• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013 - Product Image

PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013

  • ID: 2518916
  • March 2013
  • Region: Global
  • 141 Pages
  • GlobalData


  • Actavis
  • FDA
  • Merck
  • Mylan Pharmaceuticals
  • Pfizer
  • PhRMA
  • MORE

"PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013" report, provides strategic analysis of the global generics industry. It discusses key trends, significant M&A deals in 2012, and describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of the top 30 companies into various markets, including the BRIC countries (Brazil, Russia, India, and China), to identify the top players in each market.

Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions


- The report identifies the key generic players in various markets, including a special focus on emerging markets such as India, China, Russia, and Brazil.
- Furthermore, it provides detailed analysis of the various generic markets including the US, Europe, APAC, and BRIC.
- The report contains expert insights on the corporate strategies of generic companies seeking competitive advantage in the highly competitive generics industry.

Reasons to buy

- Identify the key generic players in various markets, including the emerging markets such as India, China, Russia, and Brazil
- Analyze and track the strategies that successful generic companies are using to gain share in the increasingly competitive market
- Understand the key drivers and trends in the global generics industry
- Use this information as an independent source for your due diligence and transaction strategy


  • Actavis
  • FDA
  • Merck
  • Mylan Pharmaceuticals
  • Pfizer
  • PhRMA
  • MORE

1 Tables & Figures
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Report Scope
2.2 Upcoming Related Reports
2.3 Recently Published Reports

3 Generics Industry Dynamics
3.1 Generics to the Fore
3.1.1 Imminence of the Patent Cliff
3.1.2 Rising healthcare expenditures prompts many governments to resort to generics to save costs
3.1.3 Focus on emerging markets
3.1.4 Generic companies continuously drill holes in Big Pharma's deep pockets

4 Strategic Deals Trends
4.1 Big Pharma's need to plug its revenue gap
4.2 Governments cut healthcare spending as financial austerity spreads globally
4.3 Low margins in the generics business necessitate scale economies
4.4 Highlighted Deals from 2012
4.4.1 Watson Closes $5.5 billion Purchase of Actavis
4.4.2 Mylan Enters into Generics Partnership with Pfizer
4.4.3 Merck and Supera Farma Laboratórios

5 Generics in North America
5.1 Overview
5.2 United States
5.2.1 The US Pharmaceutical Industry
5.2.2 Key Players
5.2.3 Outlook

6 Generics in the Asia-Pacific (APAC)
6.1 Overview
6.2 Australia: Healthcare Policy Reform and the Generics Business
6.2.1 Prescription Drug Regulation and Pricing in Australia
6.2.2 The Australian Generics Business Environment
6.2.3 Key Players
6.2.4 Australia's Healthcare Reform and Impact on the Role of Generics
6.3 Japan
6.3.1 The Japanese Pharmaceutical Market
6.3.2 Perception of Generics in Japan
6.3.3 Impact of Pharmacies on Generics Substitution
6.3.4 Generics Approval and Market Exclusivity
6.3.5 Key Players

7 Generics in Europe and Africa
7.1 Overview
7.2 Europe
7.2.1 The Increasing Burden on Healthcare
7.2.2 Case Study: Germany
7.3 Africa
7.3.1 The Need for Local Production
7.3.2 Low regulatory compliance and infrastructure result in a weak pharmaceutical industry
7.3.3 Low standard of living makes medicines unaffordable, discouraging local players
7.3.4 Global organizations and multinationals are standardizing Africa's pharmaceutical space
7.3.5 Pharmaceutical Manufacturing Plan for Africa
7.3.6 Case Study: South Africa

8 Generics in the BRIC Countries
8.1 Overview
8.2 Brazil
8.2.1 Latin America Market Leader
8.2.2 Government industrial policies will aid further development of the pharmaceutical industry
8.2.3 Generics in Brazil
8.2.4 Key Players
8.3 Russia
8.3.1 The New Federal Law on Health in the Russian Federation
8.3.2 Pharma 2020 will further encourage domestic production in Russia
8.3.3 Healthy financial situation places less pressure on the Russian government to reduce healthcare costs
8.3.4 Key Player
8.4 India
8.4.1 Absence of product patents before 2005 triggered the birth of the Indian generics market
8.4.2 Quality manufacturing facilities create an ideal environment for generics to thrive
8.4.3 Inter-firm competition enables capabilities development
8.4.4 Policies and initiatives encourage participation in generics manufacturing by driving demand
8.4.5 Increased competition from larger multinationals may stymie the development of smaller domestic players
8.4.6 Growing pressures on patent laws could challenge domestic generics manufacturers
8.4.7 Key Market Players
8.4.8 Outlook
8.5 China
8.5.1 Parallel demographics presents different scenarios on China's pharmaceutical industry
8.5.2 A dysfunctional healthcare system provides little incentive for generics substitution
8.5.3 Soaring healthcare expenditures pressure China's financial stability
8.5.4 Healthcare reform will level the pharmaceutical industry playing field and foster the growth of the generics sector
8.5.5 Key Players
8.5.6 Market Outlook

9 Strategic Outlook
9.1 Patent expiries and evolution of the regulatory landscape fuel generics
9.1.1 US patent expiry wave presents a unique opportunity for generic manufacturers
9.1.2 Government reforms will continue to facilitate generic prescribing
9.1.3 Consolidation sweeps through the generics sector
9.1.4 India's generic companies are an emerging force in the global generics market

10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Expert Panel Validation
10.4 About the Authors
10.4.1 Analyst
10.4.2 Director of Healthcare Industry Dynamics
10.4.3 Global Head of Healthcare Research and Consulting
10.5 About the Industry Dynamics Team
10.6 About Us
10.7 Contact Us
10.8 Disclosure Information
10.9 Disclaimer

1.1 List of Tables
Table 1: First-Time Generic Drug Approvals, 2012
Table 2: Health Expenditures of OECD Countries as a Percentage of GDP, 2001–2010
Table 3: Recent and Upcoming US Patent Expirations, with FY2011 and FY2012 Sales Data
Table 4: Overview of the Collaboration and M&A Deals in this Report, 2012
Table 5: Watson Acquires Actavis in $5.5 Billion Deal
Table 6: Pfizer's Collaboration with Mylan Pharmaceuticals
Table 7: Merck's JV with Supera Farma Laboratórios
Table 8: Generics-Focused Deals by Major Drug Companies, 2008–2012
Table 9: Initial Phase of Price Reductions through Disclosure Agreements, 2009
Table 10: Top 10 Pharmaceutical Companies in Brazil, 1998 and 2007
Table 11: China: Urban and Rural Pharmaceutical Market Size, 2012

1.2 List of Figures
Figure 1: NME Approvals by the FDA, 1996–2012
Figure 2: Trend in Deals in the Generics Industry, 2008–2012
Figure 3: Pfizer: Emerging Markets Revenues as a Percentage of Annual Revenues, 2006–2012
Figure 4: Merck: Market focus1, 2007–2011
Figure 5: North American Generics Market Landscape – FY2012 Corporate Revenue Growth vs. North American Revenue Growth
Figure 6: Domestic Exports of Pharmaceutical Products from the US, 2000–2011
Figure 7: R&D Spending by PhRMA Members, 2004-2011
Figure 8: US Healthcare Expenditures and GDP, 2002–2011
Figure 9: US per Capita Healthcare Expenditures and GDP, 2001–2010
Figure 10: FDA Generic Drug Review Process
Figure 11: Generic Drug Approvals in the US, 2008–2012
Figure 12: APAC Generics Market Landscape – FY2012 Corporate Revenue Growth vs. APAC Revenue Growth
Figure 13: Australia: Trends in Prescription Volume and Government Costs, 2000–2011
Figure 14: Australian Government's and Patients' Contributions to PBS Costs, 2005–2011
Figure 15: Average Birth Life Expectancies1 in the APAC Region, 2012
Figure 16: EMEA Generics Market Landscape – FY2012 Corporate Revenue Growth vs. EMEA Revenue Growth
Figure 17: Birth Life Expectancies in Europe, 2010 vs. 2003
Figure 18: Public-Debt and Budget-Deficit-to-GDP Ratios in the Eurozone, 2012
Figure 19: Generics vs. Branded Products Split in South Africa, 2002–2006
Figure 20: Generics vs. Branded Products Split in South Africa, 2008–2012
Figure 21: Generics Utilization in South Africa, 2012–2020
Figure 22: BRIC Generics Market Landscape – FY2012 Corporate Revenue Growth vs. BRIC Revenue Growth
Figure 23: Russia, Percentage of Total Healthcare Expenditures by Revenue Source, 2009
Figure 24: Value of Pharmaceutical Exports from India, 2002–2011
Figure 25: Indian Generics Market Landscape – FY2012 Corporate Revenue Growth vs. India Revenue Growth
Figure 26: Total and Government Healthcare Expenditures- in China, 2001–2011


  • Actavis
  • FDA
  • Merck
  • Mylan Pharmaceuticals
  • Pfizer
  • PhRMA
  • MORE

Multinationals Threatening Domestic Growth of India's Generics Firms, Says The authors Report

Previously considered a thorn in the side of Big Pharma, the Indian generics industry is emerging as a key hunting ground for Multinational Corporations (MNCs) looking to extend their reach into emerging economies. Domestic players, however, may pay the price for the intrusion, states the latest report from research and consulting firm The authors.

The new report* – the first in the company's new PharmaSphere series – explains that while the Indian generics industry has witnessed significant growth over the last year, pharmaceutical giants, which are keen to leverage the nation's relatively low cost of production and high quality facilities, may slow the growth of India's domestic companies.

Adefemi Adenuga, analyst with The authors's Industry Dynamics Team, says: “Indian generics companies, particularly the smaller ones, do not possess the capabilities to match those of these larger players, and are therefore not able to enjoy the resultant scope and scale economies, which are two key requirements in the price-sensitive generics business.”

Indeed, MNCs are actively positioning themselves to capture a significant portion of the Indian generics market, primarily through authorized generic versions of their off-patent blockbusters. Adenuga states: “The branded generics offered by these large companies may appeal more to the brand-sensitive portion of the Indian population, which now numbers over 1.2 billion, especially if these products are sold at prices that compete well with unbranded pharmaceuticals.”

The The authors analyst also believes that the future of the Indian generics market will be shaped by how its government reacts to the current pressure by MNCs regarding the nation's patent laws. Both Bayer and Novartis have launched strong challenges against India's compulsory licensing of key drugs over the last 12 months.

“Although the government is currently standing its ground, increasing pressure from Big Pharma may force it to relax some of its more stringent laws to favor foreign companies, considering the economic implications of their presence in the country.

“This will come as a blow to domestic generics manufacturers, who often reap the benefits of compulsory licenses and legal rulings against foreign multinationals.”

* PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013

This report provides strategic analysis of the global generics industry and discusses key trends, significant M&A deals in 2012, and describes the operations strategy of these companies.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by The authors's team of industry experts.

- Actavis
- Merck
- Mylan Pharmaceuticals
- Pfizer
- Supera Farma Laboratórios
- Watson

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos